Feature story
Novartis committed to new therapies for multiple sclerosis (MS) community
Recent advances in science are enabling new treatments with greater efficacy and more convenient delivery. Novartis is investing significant resources to deliver these treatments to patients with MS. more
Investors
Latest news
03-Nov-2009
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
Our products
We want to improve your quality of life.
USA • Switzerland • Germany • France • United Kingdom
MedAdNews
Novartis has been named the "Most Admired Pharmaceutical Company."
Novartis announced its results for the third quarter of 2009 on October 22.
Clinical pipeline
Our product pipeline has 148 projects in various stages of clinical development.